Stock Research for CYTX

CYTX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTX Stock Chart & Research Data

The CYTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTX Due diligence Resources & Stock Charts

The CYTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTX Detailed Price Forecast - CNN Money CNN View CYTX Detailed Summary - Google Finance
Yahoo View CYTX Detailed Summary - Yahoo! Finance Zacks View CYTX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CYTX Trends & Analysis - Trade-Ideas Barrons View CYTX Major Holders - Barrons
NASDAQ View CYTX Call Transcripts - NASDAQ Seeking View CYTX Breaking News & Analysis - Seeking Alpha
Spotlight View CYTX Annual Report - CompanySpotlight.com OTC Report View CYTX OTC Short Report - OTCShortReport.com
TradeKing View CYTX Fundamentals - TradeKing Charts View CYTX SEC Filings - Bar Chart
WSJ View Historical Prices for CYTX - The WSJ Morningstar View Performance/Total Return for CYTX - Morningstar
MarketWatch View the Analyst Estimates for CYTX - MarketWatch CNBC View the Earnings History for CYTX - CNBC
StockMarketWatch View the CYTX Earnings - StockMarketWatch MacroAxis View CYTX Buy or Sell Recommendations - MacroAxis
Bullish View the CYTX Bullish Patterns - American Bulls Short Pains View CYTX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CYTX Stock Mentions - StockTwits PennyStocks View CYTX Stock Mentions - PennyStockTweets
Twitter View CYTX Stock Mentions - Twitter Invest Hub View CYTX Investment Forum News - Investor Hub
Yahoo View CYTX Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTX - SECform4.com Insider Cow View Insider Transactions for CYTX - Insider Cow
CNBC View CYTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTX - OTC Markets
Yahoo View Insider Transactions for CYTX - Yahoo! Finance NASDAQ View Institutional Holdings for CYTX - NASDAQ


Stock Charts

FinViz View CYTX Stock Insight & Charts - FinViz.com StockCharts View CYTX Investment Charts - StockCharts.com
BarChart View CYTX Stock Overview & Charts - BarChart Trading View View CYTX User Generated Charts - Trading View


Latest Financial News for CYTX

Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
Posted on Wednesday March 28, 2018

SAN DIEGO and TOKYO, March 28, 2018-- Cytori Therapeutics, Inc. announced today that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy™ for men ...


Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant
Posted on Wednesday March 28, 2018

Stock Monitor: Cytori Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharma Holding Co. Ltd. (NYSE: ...


Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT
Posted on Monday March 12, 2018

Q4 2017 Cytori Therapeutics Inc Earnings Call


Cytori reports 4Q loss
Posted on Friday March 09, 2018

The San Diego-based company said it had a loss of 20 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share. The developer of cell therapies posted revenue of $1.5 million ...


Enter a stock symbol to view the stock details.